US equities |
INTC $64.61 ▼-29.82% AMZN $239.04 ▼-1.95% MU $902.84 ▼-3.36% NVDA $207.32 ▼-2.97% SNDK $1,221.02 ▼-8.20% GOOGL $280.88 ▼-1.04% AMD $514.46 ▼-9.17% AAPL $345.24 ▼-1.05%
FinancialContent

Alvotech - Ordinary Shares (NQ:ALVO)

4.760 -0.130 (-2.66%)
Delayed Quote Updated: 9:54 AM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alvotech - Ordinary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
From Alvotech
Via GlobeNewswire
News headline image
ALVO Stock Earnings: Alvotech Misses EPS for Q1 2024 ↗
ALVO stock results show that Alvotech missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
From Alvotech
Via GlobeNewswire
News headline image
Stocks Hold Steady On Mixed Fed Remarks, First Solar Rallies, Bitcoin Falls Below $70,000: What's Driving Markets Tuesday? ↗
It’s a rather quiet session on Tuesday, with major U.S. averages trading around the flatline at midday trading in New York. 
Via Benzinga
Topics Economy
News headline image
ALVO Stock Earnings: Alvotech Reported Results for Q4 2023 ↗
Alvotech just reported results for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
From Alvotech
Via GlobeNewswire
News headline image
Alvotech's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
From Alvotech
Via GlobeNewswire
News headline image
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
From Alvotech
Via GlobeNewswire
News headline image
Fifth Third Bancorp Reports Upbeat Earnings, Joins Metropolitan Bank Holding, Paramount Global And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
From Alvotech
Via GlobeNewswire
News headline image
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday ↗
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday. 
Via Benzinga
Topics Stocks
News headline image
Alvotech Announces Increase in Number of Own Shares
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
From Alvotech
Via GlobeNewswire
News headline image
Earnings Scheduled For March 20, 2024 ↗
Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ:TIGR) is expected to report quarterly earnings at $0.07 per share on revenue of $207.00 million. 
Via Benzinga
News headline image
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
Alvotech to host Capital Markets Day in Reykjavik and on-line on March 22, 2024 
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Appoints Interim Chief Quality Officer
From Alvotech
Via GlobeNewswire
News headline image
TEVA Stock Pops 4% as Teva Receives FDA Approval ↗
Teva Pharmaceutical stock is rising higher on Monday after partner company Alvotech got approval from the FDA for a Humira biosimilar. 
Via InvestorPlace
News headline image
Why Is Generic Drugs Player Teva Pharma Stock Trading Higher Today? ↗
FDA-approved Simlandi (adalimumab-ryvk): a high-concentration biosimilar to Humira for rheumatoid arthritis, psoriasis, and more. 
Via Benzinga
News headline image
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
From Alvotech
Via GlobeNewswire
News headline image
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
From Alvotech
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >